NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ATAI

ATAI Life Sciences N.V

Jul 01 • 04:00PM ET

2.71

Dollar change +0.52
Percentage change 23.74	%

Healthcare • Biotechnology • Germany • NASD

Peers: CMPS MNMD GHRS CYBN RLMD SLS ANIX RGLS VNDA

| Held by: VHT PSIL GWX QQQS AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.80	Insider Own	31.72%	Shs Outstand	199.78M	Perf Week	28.44%
Market Cap	544.04M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	24.31%	Shs Float	137.08M	Perf Month	17.32%
Enterprise Value	465.03M	PEG	-	EPS next Q	-0.12	Inst Own	9.91%	Short Float	8.00%	Perf Quarter	99.26%
Income	-128.60M	P/S	1648.61	EPS this Y	46.70%	Inst Trans	15.44%	Short Ratio	5.07	Perf Half Y	116.80%
Sales	0.33M	P/B	3.56	EPS next Y	-7.70%	ROA	-50.86%	Short Interest	10.96M	Perf YTD	103.76%
Book/sh	0.76	P/C	5.03	EPS next 5Y	30.52%	ROE	-62.43%	52W High	2.64 2.65%	Perf Year	105.30%
Cash/sh	0.54	P/FCF	-	EPS past 3/5Y	3.72% 18.62%	ROIC	-77.36%	52W Low	1.03 163.11%	Perf 3Y	-28.50%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-75.27% -	Gross Margin	-5.44%	Volatility	9.07% 9.35%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1409.19	EPS Y/Y TTM	-89.51%	Oper. Margin	-31987.01%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.07	Sales Y/Y TTM	-0.90%	Profit Margin	-38852.87%	RSI (14)	66.49	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.07	EPS Q/Q	-30.12%	SMA20	18.57%	Beta	1.45	Target Price	9.20
Payout	-	Debt/Eq	0.19	Sales Q/Q	8538.89%	SMA50	40.33%	Rel Volume	23.77	Prev Close	2.19
Employees	54	LT Debt/Eq	0.09	Earnings	May 14 BMO	SMA200	71.68%	Avg Volume	2.16M	Price	2.71
IPO	Jun 18, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.08% -	Trades		Volume	51,392,639	Change	23.74%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Reiterated	H.C. Wainwright	Buy	$15 → $10
Apr-03-24	Upgrade	Maxim Group	Hold → Buy	$6
Nov-01-22	Initiated	Loop Capital	Buy	$18
Nov-30-21	Initiated	Maxim Group	Buy	$25
Nov-11-21	Initiated	ROTH Capital	Buy	$32
Oct-18-21	Initiated	H.C. Wainwright	Buy	$40
Sep-01-21	Initiated	Jefferies	Buy	$27
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform	$19
Jul-13-21	Initiated	Credit Suisse	Outperform	$25
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Citigroup	Buy	$26
Jul-13-21	Initiated	Cantor Fitzgerald	Buy	$45
Jul-13-21	Initiated	Canaccord Genuity	Buy	$28
Jul-13-21	Initiated	Berenberg	Buy	$35
Jul-08-21	Initiated	Aegis Capital	Buy	$26

Show Previous Ratings

Today 03:06PM	A Promising Depression Drug Works. Psychedelics Are Back. (Barrons.com) +23.74%
12:04PM	atai and Beckley Psytechs psychedelic wins in Phase IIb depression trial (Clinical Trials Arena)
07:15AM	Atai and Beckley, set to merge, reveal study success for psychedelic drug (BioPharma Dive)
06:05AM	atai Life Sciences Announces $50 Million Private Placement Financing (GlobeNewswire)
06:00AM	atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression (GlobeNewswire)
09:40AM	Loading…
Jun-25-25 09:40AM	Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? (Zacks)
Jun-24-25 03:51PM	Maxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price Target (Insider Monkey)
Jun-23-25 09:51AM	Compasss Psychedelic Drug to Treat Depression Meets Goal in Trial (Bloomberg) -18.55%
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
12:01AM	This Illegal Psychedelic Is Hailed as a Revolutionary Breakthrough (WSJ)
Jun-09-25 12:00PM	Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice (Zacks) -5.39%
09:40AM	Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-02-25 06:00AM	atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies (GlobeNewswire) +7.79%
May-29-25 08:30AM	atai Life Sciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
12:00PM	Loading…
May-23-25 12:00PM	atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know (Zacks)
May-22-25 09:55AM	atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +5.76%
09:40AM	Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? (Zacks)
May-21-25 12:10PM	Phase 2a data for BPL-003 encouraging for Atai Life Sciences, says Jefferies (TipRanks) -6.83%
11:55AM	Home Depot backs outlook as U.S. sales ticked up: Morning Buzz (TipRanks)
May-20-25 07:00AM	atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression (GlobeNewswire) +11.41%
May-14-25 07:00AM	atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates (GlobeNewswire)
May-13-25 07:01AM	atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder (GlobeNewswire)
Apr-21-25 08:46AM	Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating (Seeking Alpha)
Apr-11-25 11:05AM	Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial (TipRanks) +6.61%
Apr-02-25 03:35PM	Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds? (Insider Monkey) +19.35%
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks) +5.84%
Mar-17-25 08:00AM	atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks) +6.47%
07:00AM	Loading…
Mar-11-25 07:00AM	atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression (GlobeNewswire)
Mar-05-25 07:00AM	atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression (GlobeNewswire)
Mar-01-25 11:08AM	Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-24-25 04:10PM	atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -8.54% -5.49%
Feb-20-25 07:00AM	atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares (GlobeNewswire)
Feb-12-25 10:47PM	atai Life Sciences Announces Pricing of Public Offering of Common Shares (GlobeNewswire) +14.35% -10.98%
04:01PM	atai Life Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Feb-03-25 08:24AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +19.35%
Jan-28-25 07:00AM	atai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder (GlobeNewswire)
Jan-12-25 07:58PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-10-25 07:00AM	atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health (GlobeNewswire) -7.41%
Nov-13-24 08:00AM	atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.53%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire) +12.06%
Oct-15-24 08:00AM	atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-04-24 07:00AM	atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 07:10AM	atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:00AM	atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT) (GlobeNewswire)
Aug-07-24 07:00AM	atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) -5.11%
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +10.61%
Jul-08-24 07:45AM	3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers (InvestorPlace)
Jul-06-24 07:21AM	3 Psychedelic Stocks to Ride to the Moon and Beyond (InvestorPlace)
Jul-03-24 09:48AM	Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns (InvestorPlace)
Jul-02-24 03:43PM	3 Psychedelic Stocks to Buy on the Dip: Summer 2024 (InvestorPlace)
Jun-26-24 07:00AM	atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference (GlobeNewswire)
06:09AM	atai Life Sciences co-CEO says initial results from ELE-101 show promise in treating depression (News Direct)
Jun-20-24 07:00AM	atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a (GlobeNewswire)
May-31-24 07:00AM	atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference (GlobeNewswire) -6.55%
May-23-24 07:00AM	atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors (GlobeNewswire)
May-15-24 12:54PM	ATAI Stock Earnings: ATAI Life Sciences Beats EPS for Q1 2024 (InvestorPlace) +7.33%
06:59AM	atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Apr-24-24 07:00AM	atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression (GlobeNewswire) -5.08%
Apr-17-24 07:00AM	atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology (GlobeNewswire) -7.91%
Mar-28-24 07:00AM	atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights (GlobeNewswire) +10.06%
Mar-27-24 07:00AM	atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression (GlobeNewswire)
Mar-19-24 08:00AM	The Next Great Biotech Boom Has Arrived (PR Newswire)
Mar-12-24 12:35PM	atai Life Sciences advances VLS-01 for treatment-resistant depression (News Direct) -5.45%
Mar-04-24 08:00AM	atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 (GlobeNewswire)
Feb-28-24 05:00PM	atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-06-24 05:00PM	atai Life Sciences Appoints Anne Johnson as Chief Financial Officer (GlobeNewswire) -5.03%
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire)
Jan-07-24 10:15PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-05-24 08:54AM	Ecstasy-for-Medicine Advocate Raises $100 Million (The Wall Street Journal)
08:00AM	Legalization Advocate MAPS Raises Money for Pharmaceutical Psychedelics (The Wall Street Journal)
Jan-04-24 07:00AM	atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics (GlobeNewswire) +14.67%
Jan-02-24 08:00AM	atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA) (GlobeNewswire) +19.86%
Nov-14-23 07:03AM	atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights (GlobeNewswire) +9.13%
Oct-15-23 05:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-10-23 08:00AM	ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT (PR Newswire)
Oct-06-23 04:05PM	atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit (GlobeNewswire) -8.55%
Oct-02-23 04:13PM	atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants (GlobeNewswire) +12.10%
Sep-14-23 11:02PM	Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NV (GuruFocus.com)
08:02AM	atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-06-23 04:01PM	atai Life Sciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-10-23 06:59AM	atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) (GlobeNewswire)
Aug-08-23 04:02PM	atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) (GlobeNewswire)
Jun-28-23 09:37AM	Ecstasy-for-Medicine Advocate Seeks Cash Lifeline (The Wall Street Journal) +7.89%
Jun-01-23 09:10AM	Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
06:59AM	atai Life Sciences to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-11-23 06:59AM	atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates (GlobeNewswire)
May-02-23 05:20PM	atai Life Sciences to Participate in Upcoming May Investor Conference (GlobeNewswire)
Apr-28-23 06:59AM	atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting (GlobeNewswire)
Apr-13-23 06:59AM	atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) (GlobeNewswire) +9.89%
Apr-03-23 07:00AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research) +13.12%
Mar-24-23 06:59AM	atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights (GlobeNewswire) +5.04%
Mar-06-23 07:00AM	atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates (GlobeNewswire)
Mar-01-23 04:01PM	atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Jan-19-23 01:24PM	This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks (Benzinga)
Jan-17-23 05:00AM	Trippy Trading: Top Psychedelic Stocks For 2023 (News Direct) +7.78%

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAHIL KIRPEKAR	Officer	Jul 01 '25	Proposed Sale	2.77	106,093	294,381		Jul 01 04:16 PM
SAHIL KIRPEKAR	Officer	Jun 04 '25	Proposed Sale	2.48	80,000	198,408		Jun 04 04:22 PM
Kirpekar Sahil	Chief Business Officer	Mar 21 '25	Sale	1.35	48,563	65,560	115,636	Mar 24 09:00 PM
Craig Kevin James	Chief Medical Officer	Mar 21 '25	Sale	1.35	11,563	15,610	8,437	Mar 24 09:00 PM
Rao Srinivas	See Remarks	Mar 21 '25	Sale	1.35	75,418	101,814	212,942	Mar 24 09:00 PM
Johnson Anne Nagengast	Chief Financial Officer	Mar 21 '25	Sale	1.35	33,545	45,286	140,045	Mar 24 09:00 PM
Short Glenn Frank	Chief Scientific Officer	Mar 21 '25	Sale	1.35	13,161	17,767	42,333	Mar 24 09:00 PM
FLORIAN BRAND	Officer	Mar 24 '25	Proposed Sale	1.54	100,000	154,090		Mar 24 05:10 PM
Apeiron Investment Group Ltd.	10% Owner	Mar 24 '25	Buy	1.40	1,800,000	2,520,000	42,369,415	Mar 24 05:00 PM
Brand Florian	Former Officer	Mar 19 '25	Proposed Sale	1.39	184,451	256,387		Mar 21 06:49 PM
Craig Kevin James	Officer	Mar 21 '25	Proposed Sale	1.39	11,563	16,073		Mar 21 06:46 PM
Short Glenn Frank	Officer	Mar 21 '25	Proposed Sale	1.39	13,161	18,294		Mar 21 06:42 PM
Johnson Anne Nagengast	Officer	Mar 21 '25	Proposed Sale	1.39	33,545	46,628		Mar 21 06:39 PM
Rao Srinivas	Officer	Mar 21 '25	Proposed Sale	1.39	75,418	104,831		Mar 21 06:35 PM
Kirpekar Sahil	Officer	Mar 21 '25	Proposed Sale	1.39	48,563	67,503		Mar 21 06:32 PM
FLORIAN OLAF BRAND	Officer	Mar 20 '25	Proposed Sale	1.38	300,000	412,560		Mar 20 04:39 PM
Apeiron Investment Group Ltd.	10% Owner	Feb 14 '25	Buy	2.10	10,835,718	22,755,008	40,555,215	Feb 19 06:00 PM
ATAI Life Sciences N.V.	10% Owner	Sep 26 '24	Sale	6.05	2,660,000	16,093,000	6,905,774	Sep 27 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATAI

ATAI Life Sciences N.V

Upgrade your FINVIZ experience